Rising surgical demand, increase in HAIs driving sepsis therapeutics market: 4 highlights

The sepsis therapeutics market is set to expand over the next several years, a Transparency Market Research report found, according to medGadget.

Here are four highlights:

1. North American leads the market due to a high incidence of sepsis and more public awareness about sepsis complications. Sepsis infected 1.16 million U.S. residents annually last year.

2. A growing incidence rate and increased sepsis research is fueling European growth.

3. Factors spurring expansion include a higher prevalence of hospital-acquired infections and an increasing surgical demand.

4. Companies operating in the market include:
●    Adrenomed
●    Altor BioScience Corp.
●    Boehringer Ingelheim
●    Bristol-Myers Squibb Co.
●    InflaRx
●    Inotrem

More articles on quality and infection control:
Theranos paying Arizona residents $4.65M, won't operate lab for two years: 4 key notes
WHO Surgical Safety Checklist reduces postsurgical deaths: 2 study insights
HAI control market to surpass $82.9B by 2020 at 8.5% CAGR: 5 key points

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Patient Safety Tools & Resources Database

Top 40 Articles from the Past 6 Months